| IPO Company Profile © ipodata.com |
| Message Board | Quote | Chart | News | SEC Filings | Peer IPO Companies |
| Genomic Solutions, Inc. |
| 4355 Varsity Drive, Suite E, Ann Arbor, MI 48108 * (734) 975-4800 |
| Business Description | The company designs and develops genomic and proteomic instrumentation, software and services. |
| Offering Information Company has | |||
| Trading As | GNSL (NASNTL) | Industry | Pharmaceutical (SIC 2834) |
| Type of Stock Offered | Common Shares | Filing Date | 2/11/00 |
| Domestic Shares Offered | 7,000,000 | Offer Date | 5/4/00 |
| Foreign Shares Offered | 0 | Filing Range | $17.00 - $19.00 |
| Company Shares | 7,000,000 | Offer Price | $8.00 |
| Selling Shrhldrs Shares | 0 | Gross Spread | $0.560 |
| Gross Proceeds | $56,000,000 | Selling | $0.340 |
| Expenses | - - | Reallowance | $0.100 |
| Post-IPO Shares | 22,720,000 | Employees | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| Warburg Dillon Read LLC | Lead Manager | (203) 719-3000 |
| Dain Rauscher Wessels | Co-manager | (612) 371-2818 |
| Punk, Ziegel & Knoell | Co-manager | (212) 308-9494 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | - - Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/97 | 12/31/98 | 12/31/99 | ||||
| Revenues | - | - | 2.164 | 5.507 | 12.092 | - | - |
| Income from Oper. | - | - | -3.617 | -7.825 | -8.818 | - | - |
| Net Income | - | - | -1.991 | -7.786 | -11.142 | - | - |
| E.P.S | - | - | -6.930 | -2.710 | -3.750 | - | - |
| Revenue Growth (%) | - | - | 154.48 | 119.575 | - | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -9.52 | - | - | ||||
| Cash Flow - Inv. | -1.79 | - | - | ||||
| Cash Flow - Fin. | 9.87 | - | - | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 12/31/99 | Financial Ratios | ||||
| Total Assets | 13.86 | Current Assets | 7.02 | Current Ratio | 1.00 |
| Total Liab. | 23.24 | Current Liab. | 7.02 | Debt Ratio | 167.70% |
| Total Equity | -9.38 | Working Cap. | 0.00 | Debt to Equity Ratio | - |
| Cash | 1.33 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used to repay debt, for general corporate purposes and possible future acquisitions. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Jaffe, Raitt, Heuer & Weiss, P.C. |
| Bank's Law Firm | Mintz, Levin, Cohn, Ferris, Glovsky And Popeo |
| Registrar/Transfer Agent | American Securities Transfer and Trust |
| Auditor | Arthur Andersen |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| Chase Venture Capital Associates, L.P. | 29.30 | |
| American Healthcare Fund II | 11.10 | |
| PerkinElmer, Inc. | 7.70 | |
| Note: represents ownership of 5% or more prior to the offering. | ||